Barclays
FDMT icon

Barclays’s 4D Molecular Therapeutics FDMT Stock Holding History

Barclays’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Sell
23,825
-1,612
-6% -$15.7K ﹤0.01% 3468
2026
Q1 		$237K Sell
25,437
-145,202
-85% -$1.26M ﹤0.01% 3589
2025
Q4 		$1.28M Buy
170,639
+76,811
+82% +$779K ﹤0.01% 3264
2025
Q3 		$815K Sell
93,828
-17,951
-16% -$107K ﹤0.01% 3493
2025
Q2 		$415K Buy
111,779
+14,737
+15% +$51.8K ﹤0.01% 3866
2025
Q1 		$313K Sell
97,042
-8,203
-8% -$38.6K ﹤0.01% 3808
2024
Q4 		$586K Sell
105,245
-9,603
-8% -$75.4K ﹤0.01% 3728
2024
Q3 		$1.24M Buy
114,848
+67,202
+141% +$1.12M ﹤0.01% 3213
2024
Q2 		$1M Sell
47,646
-173
-0.4% -$4.34K ﹤0.01% 2601
2024
Q1 		$1.52M Sell
47,819
-60,890
-56% -$1.55M ﹤0.01% 2789
2023
Q4 		$2.2M Buy
108,709
+34,774
+47% +$458K ﹤0.01% 2839
2023
Q3 		$941K Sell
73,935
-68,529
-48% -$1.15M ﹤0.01% 2375
2023
Q2 		$2.57M Buy
142,464
+85,235
+149% +$1.57M ﹤0.01% 1718
2023
Q1 		$984K Buy
57,229
+22,556
+65% +$439K ﹤0.01% 2743
2022
Q4 		$770K Buy
34,673
+23,297
+205% +$360K ﹤0.01% 3008
2022
Q3 		$91K Buy
11,376
+1,760
+18% +$15.9K ﹤0.01% 3571
2022
Q2 		$68K Sell
9,616
-2,340
-20% -$22.7K ﹤0.01% 3924
2022
Q1 		$181K Buy
+11,956
New +$188K ﹤0.01% 3480

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Barclays's FDMT Position: Q2 2026 in Review

Barclays reduced its 4D Molecular Therapeutics (FDMT) stake by 6.3% in Q2 2026, selling an estimated $15.7K and leaving 23,825 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #3468.

Barclays first reported a position in FDMT in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.57M in Q2 2023. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Barclays held 23,825 shares of 4D Molecular Therapeutics worth $317K as of Q2 2026.
  • Barclays sold 1,612 4D Molecular Therapeutics shares in Q2 2026, an estimated $15.7K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3468 holding.
  • Barclays first reported a position in 4D Molecular Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's 4D Molecular Therapeutics position peaked at $2.57M in Q2 2023.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.